Clinical Phenotypes of COVID-19 Associated Mucormycosis (CAM): A Comprehensive Review

被引:5
|
作者
Almyroudi, Maria Panagiota [1 ]
Akinosoglou, Karolina [2 ]
Rello, Jordi [3 ]
Blot, Stijn [4 ,5 ]
Dimopoulos, George [6 ]
机构
[1] Natl & Kapodistrian Univ Athens, Univ Hosp Attikon, Med Sch, Dept Emergency Med, Athens 12462, Greece
[2] Univ Patras, Univ Gen Hosp Patras, Sch Med, Dept Internal Med & Infect Dis, Rion 26504, Greece
[3] CHU Nimes, Vall dHebron Inst Res, Spain & Clin Res, Barcelona, F-30900 Nimes, France
[4] Univ Ghent, Dept Internal Med & Pediat, B-9000 Ghent, Belgium
[5] Univ Queensland, Fac Med, UQ Ctr Clin Res, Brisbane 4029, Australia
[6] Natl & Kapodistrian Univ Athens, EVGENIDIO Hosp, Med Sch, Dept Crit Care 3, Athens 11528, Greece
关键词
mucorales; invasive fungal infections; SARS-CoV-2; diabetes mellitus; rhino-orbito-cerebral mucormycosis; ORBITAL-CEREBRAL MUCORMYCOSIS; COVID-19-ASSOCIATED MUCORMYCOSIS; CARE CENTER; MANAGEMENT; SPECTRUM; PROFILE;
D O I
10.3390/diagnostics12123092
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A mucormycosis surge was reported during the COVID-19 pandemic in India. A literature search until 14 July 2022, with the aim of updating COVID-19-associated mucormycosis (CAM), identified 663 studies and 88 met inclusion criteria (8727 patients). India reported 8388 patients, Egypt 208 and Europe 40. Rhino-orbito-cerebral mucormycosis (ROCM) was identified among 8082 (98.3%) patients, followed by 98 (1.2%) with pulmonary. In India, 82.6% of patients had diabetes mellitus, with 82% receiving corticosteroids. In Europe, 75% presented pulmonary CAM, 32.5% had diabetes and 40% were immunocompromised. CAM was identified at a median of 17.4 days (IQR 7.5 days) post COVID-19 diagnosis, and PCR was performed in five studies. Rhino-orbital invasion is clinically obvious, while cerebral involvement presents with cavernous sinus thrombosis, meningitis and cerebrovascular disease. Symptoms of pulmonary CAM usually overlap with severe COVID-19 pneumonia. High-dose liposomal Amphotericin B (and early surgical debridement in ROCM) are the mainstay of therapy. The median mortality rate was estimated to be 21.4% (IQR 31.9%), increased by the presence of pulmonary (80% (IQR 50%) or cerebral involvement (50% (IQR 63.9%). In summary, different CAM clinical phenotypes need to be distinguished, influenced by geographical presentation. Opportunities exist for diagnosis and therapy optimization, based on earlier high-dose antifungal therapy, early source control, strict glycemic control and restriction of steroids to COVID-19 patients with oxygen requirements.
引用
收藏
页数:28
相关论文
共 50 条
  • [21] COVID19 associated mucormycosis: A review
    Palanisamy, Priyadharsini R.
    Elango, Dhivya
    JOURNAL OF FAMILY MEDICINE AND PRIMARY CARE, 2022, 11 (02) : 418 - 423
  • [22] Zygomaticomaxillary Osteomyelitis due to COVID-19 Associated Mucormycosis (CAM): A Case Series of 10 Patients
    Datarkar, Abhay N.
    Daware, Surendra
    Gadve, Vandana
    Pardiwala, Arwa F.
    Pund, Mahesh
    Bhawalkar, Amit
    Purohit, Subodh
    Relan, Priyanka
    Ghormade, Ashlesha
    JOURNAL OF MAXILLOFACIAL & ORAL SURGERY, 2022, 23 (6): : 1542 - 1552
  • [23] An interesting report of COVID-19 associated mucormycosis (CAM) cases by two different species of Mucorales
    Kaur, Harsimran
    Kanaujia, Rimjhim
    Nayak, Gyanaranjan
    Ramavat, Anurag Snehi
    Patro, Sourabha
    Ghosh, Anup
    Chakrabarti, Arunaloke
    Rudramurthy, Shivaprakash M.
    INDIAN JOURNAL OF MEDICAL MICROBIOLOGY, 2024, 50
  • [24] COVID-19 associated with concomitant mucormycosis and aspergillosis
    Lai, Chih-Cheng
    Wu, Chi-Jung
    Lee, Yi-Chien
    Liu, Wei-Lun
    JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2022, 55 (02) : 353 - 354
  • [25] Fatal disseminated mucormycosis associated with COVID-19
    Horiguchi, Tomoya
    Tsukamoto, Tetsuya
    Toyama, Yoko
    Sasaki, Toshiharu
    Nakamura, Tomoyuki
    Sakurai, Aki
    Kuriyama, Naohide
    Komatsu, Satoshi
    Shigeyasu, Yoshiko
    Ina, Takuma
    Sakurai, Eiko
    Nakajima, Noriko
    Tsuchimori, Arisa
    Yamada, Seiji
    Suzuki, Tadaki
    Imaizumi, Kazuyoshi
    RESPIROLOGY CASE REPORTS, 2022, 10 (03):
  • [26] COVID-19 associated mucormycosis: a case series
    Vigdorovits, A.
    Tica, O.
    Terniceanu, S.
    Ardelean, A.
    Venter, C.
    Rosca, E.
    Venter, A. C.
    VIRCHOWS ARCHIV, 2022, 481 (SUPPL 1) : S293 - S294
  • [27] A Comprehensive Review of Cutaneous Manifestations Associated with COVID-19
    Rahimi, Hoda
    Tehranchinia, Zohreh
    BIOMED RESEARCH INTERNATIONAL, 2020, 2020
  • [28] Agents of mucormycosis outbreak associated with COVID-19
    Wahab, Shadma
    Muzammil, Khursheed
    Nasir, Nazim
    ul Hasan, Atiq
    Siddiqui, Zeba
    Aggarwal, Pradeep
    Nasir, Sumbul
    ANNALS OF PHYTOMEDICINE-AN INTERNATIONAL JOURNAL, 2021, 10 : 41 - 55
  • [29] COVID-19-Associated Mucormycosis (CAM): An Updated Evidence Mapping
    Hussain, Salman
    Baxi, Harveen
    Riad, Abanoub
    Klugarova, Jitka
    Pokorna, Andrea
    Slezakova, Simona
    Licenik, Radim
    Najmi, Abul Kalam
    Klugar, Miloslav
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (19)
  • [30] COVID-19 associated pulmonary mucormycosis: A systematic review of published cases with review of literature
    Rai, Deependra K.
    JOURNAL OF FAMILY MEDICINE AND PRIMARY CARE, 2022, 11 (04) : 1244 - 1249